



# IDEAYA Biosciences

Improving Lives  
Through Transformative  
Precision Medicines

NASDAQ: **IDYA**  
September 2022

## IDEAYA Highlights

**Breakthrough Science** on transformative programs in Synthetic Lethality – an emerging area of precision medicine

**Broad Pipeline** of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

**Proven Management Team** with deep business and scientific experience has built leading oncology companies

**Pharma Strategic Partnerships** with GlaxoSmithKline<sup>1</sup>, including ~\$2 billion in potential cash milestones, Pfizer<sup>2</sup> and Amgen<sup>3</sup>

**Strong Balance Sheet** of ~\$419 million<sup>4</sup> with capital efficient model, anticipated to fund operations into 2025

**Analyst Coverage** by JP Morgan, Guggenheim, Jefferies, Oppenheimer, RW Baird, Stifel and Wedbush

(1) GSK Collaboration, Option and License Agreement ; (2) Pfizer Clinical Trial Collaboration and Supply Agreements; (3) Amgen Clinical Trial Collaboration and Supply Agreement; (4)) Includes aggregate of ~\$323.8M cash, cash equivalents and marketable securities as of June 30, 2022, plus pro forma estimated aggregate proceeds from (1) follow-on public offering as of closing September 19, 2022 (\$86.5M, net of underwriter fees) and (2) sales of common stock under the at-the-market offering from July 1, 2022 through September 13, 2022 (\$9.0M ATM, net of sales agent fees)

# IDEAYA Biosciences – Fact Sheet

**Founded 2015** on the thesis that Synthetic Lethality would emerge as a central focus of precision medicine oncology, with significant Pharma interest and the potential to develop *first-in-class* therapeutics for biomarker-defined cancer patient populations.

**Broad Pipeline** of clinical and preclinical precision medicine oncology programs with defined patient biomarkers, including

- *IDE397* targeting MAT2A for patients having tumors with MTAP deletion, a population estimated to represent ~ 15% of all solid tumors,
- *Darovasertib (IDE196)* targeting PKC for patients having GNAQ /GNA11 mutations, including metastatic uveal melanoma (MUM) or skin melanoma,
- *PARG* for patients having tumors with HRD mutations or other genetic and/or molecular signatures,
- *Pol Theta* for patients with tumors having mutations in BRCA or other homologous recombination deficiency (HRD),
- *Werner Helicase* for patients having tumors with high microsatellite instability, and
- MTAP-SL and Synthetic Lethality Targets (SLT1, SLT2), undisclosed synthetic lethality targets for molecularly-defined patient populations.

**Proven Management Team** with deep business and scientific experience has built leading oncology biotech companies, led by CEO Yujiro S. Hata, M.B.A., an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients.

**Scientific Advisory Board** includes world-class scientists who are key opinion leaders in precision medicine oncology and synthetic lethality, including SAB Chair Frank McCormick, Ph.D. (UCSF), and Bill Sellers, M.D. (Broad Institute, Novartis).

**Pharma Strategic Partnerships and Collaborations** with GlaxoSmithKline<sup>1</sup>, Pfizer<sup>2</sup> and Amgen<sup>3</sup>. The GSK strategic partnership validates IDEAYA's Synthetic Lethality platform and enhances the companies' collective leadership in Synthetic Lethality. IDEAYA and GSK are collaborating on two programs – *Pol Theta* and *Werner Helicase*. IDEAYA retains commercial rights of 50% US profit-share and ex-US royalties for *Werner Helicase*, and worldwide royalties for *Pol Theta*, with potential to earn up to approximately \$2 billion in aggregate cash milestones across the two programs.

**Strong Balance Sheet** of ~\$419 million<sup>4</sup>, with a capital efficient model, is anticipated to fund planned operations into 2025, supporting clinical data milestones across multiple programs, including for *IDE397* – targeting MAT2A in MTAP-deletion tumors and for darovasertib – targeting PKC in Metastatic Uveal Melanoma (MUM) and other GNAQ/11 mutation tumors, such as skin melanoma

**Analyst Coverage** by JP Morgan, Guggenheim, Jefferies, Oppenheimer, RW Baird, Stifel and Wedbush.

(1) GSK Collaboration, Option and License Agreement; (2) Pfizer Clinical Trial Collaboration and Supply Agreements; (3) Amgen Clinical Trial Collaboration and Supply Agreement; (4) Includes aggregate of ~\$323.8M cash, cash equivalents and marketable securities as of June 30, 2022, plus pro forma estimated aggregate proceeds from (1) follow-on public offering as of closing September 19, 2022 (\$86.5M, net of underwriter fees) and (2) sales of common stock under the at-the-market offering from July 1, 2022 through September 13, 2022 (\$9.0M ATM, net of sales agent fees)